Giles offloads life science arm to Oamps
Oamps Special Risks is understood to have bought Giles’ life sciences division.
In April, Giles MD Sarah Lyons confirmed the broker's intention to sell the Orpington-based operation.
She added then that the sale formed part of the strategy within the company to focus on key growth areas: "The life sciences operation is a small part of Giles and as such is not a driver for future growth. We have taken to decision now to sell as part of our overall development strategy which will allow us to focus on those parts of the business where we see the most growth."
The acquisition
Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.
To access these options, along with all other subscription benefits, please contact info@insuranceage.co.uk.
You are currently unable to print this content. Please contact info@insuranceage.co.uk to find out more.
You are currently unable to copy this content. Please contact info@insuranceage.co.uk to find out more.
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email info@insuranceage.co.uk
Copyright Infopro Digital Limited. All rights reserved.
You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/
If you would like to purchase additional rights please email info@insuranceage.co.uk
Most read
- Covéa cuts losses but underwriting deficit grows
- In Depth: Managing cyber risk in an ever-changing security landscape
- JMG strikes its biggest deal of 2024 with BQI swoop